Naltrexone transmucosal - Bionex Pharmaceuticals

Drug Profile

Naltrexone transmucosal - Bionex Pharmaceuticals

Latest Information Update: 16 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bionex Pharmaceuticals
  • Class Analgesics; Cyclopropanes; Drug withdrawal therapies; Irritable bowel syndrome therapies; Morphinans; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Alcoholism

Most Recent Events

  • 16 Nov 2016 Chemical structure information added
  • 14 Nov 2016 Early research development is ongoing for Alcoholism in USA (Bionex Pharmaceuticals website, November 2016)
  • 30 Sep 2012 Bionex Pharmaceuticals receives phase II SBIR grant from National Institute on Alcohol Abuse and Alcoholism for naltrexone transmucosal development in Alcoholism (3207875; Bionex Pharmaceutical website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top